Envoy Medical, Inc.
Datakwaliteit: 100%
€ 0,64
▼
€ 0,02
(-3,47%)
Marktkapitalisatie: 49,20 M
Prijs
€ 0,64
Marktkapitalisatie
49,20 M
Dagbereik
€ 0,64 — € 0,67
52-Weeksbereik
€ 0,36 — € 1,91
Volume
107.773
Openen € 0,67
50D / 200D Gem.
€ 0,68
6,35% below
50D / 200D Gem.
€ 0,96
33,58% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -18,38 M
Capital intensive — 74,27% of revenue goes to capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)7,11%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC-3219,27%
Net Margin-9857,26%
Op. Margin-9240,66%
Veiligheid
Debt / Equity
N/A
Current Ratio0,64
Interest Coverage-14,01
Waardering
PE (TTM)
-2,07
Onder sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -2,1 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,4 |
| Net Margin % | -9857,3 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7,11% | Revenue Growth (3Y) | -12,67% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 241.000,0 | Net Income (TTM) | -23,76 M |
| ROE | N/A | ROA | -262,77% |
| Gross Margin | N/A | Operating Margin | -9240,66% |
| Net Margin | -9857,26% | Free Cash Flow (TTM) | -18,38 M |
| ROIC | -3219,27% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,64 |
| Interest Coverage | -14,01 | Asset Turnover | 0,03 |
| Working Capital | -3,23 M | Tangible Book Value | -7,66 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2,07 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 204,17 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -37,35% | ||
| Market Cap | 49,20 M | Enterprise Value | 49,20 M |
| Per Share | |||
| EPS (Diluted TTM) | -1,23 | Revenue / Share | 0,00 |
| FCF / Share | -0,24 | OCF / Share | -0,24 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 74,27% | FCF Conversion | 77,37% |
| SBC-Adj. FCF | -19,00 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 241.000,0 | 225.000,0 | 316.000,0 | — | — |
| Net Income | -23,76 M | -20,80 M | -29,91 M | 19,23 M | -251.633,0 |
| EPS (Diluted) | -1,23 | -1,49 | -2,38 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -22,27 M | -19,26 M | -18,37 M | -4,89 M | -5,20 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 12,49 M | 10,18 M | 8,96 M | — | — |
| SG&A Expenses | — | — | 7,28 M | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 1,59 M | 816.000,0 | — | — | — |
| Income Tax | — | — | — | 1,50 M | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 8,56 M | 11,54 M | 7,64 M | 430,62 M | 426,90 M |
| Total Liabilities | 20,33 M | 30,38 M | 9,40 M | 18,79 M | 38,62 M |
| Shareholders' Equity | -12,16 M | -18,84 M | -1,76 M | -17,91 M | -36,71 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | — | — | 4,22 M | 107.773,0 | 149.845,0 |
| Current Assets | 6,28 M | 9,38 M | 6,83 M | 220.422,0 | 863.167,0 |
| Current Liabilities | 11,56 M | 7,54 M | 6,64 M | 7,31 M | 2,68 M |
{"event":"ticker_viewed","properties":{"ticker":"COCH","listing_kind":"stock","pathname":"/stocks/coch","exchange":"Nasdaq","country":"US"}}